These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19739879)

  • 1. Drug use evaluation of sitagliptin dosing by pharmacist versus nonpharmacist clinicians in an internal medicine department of a private physician-owned multispecialty clinic.
    McFarland MS; Cross LB; Gross B; Gentry C; Tunney J; Patel UP
    J Manag Care Pharm; 2009 Sep; 15(7):563-7. PubMed ID: 19739879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Modification of Diet in Renal Disease Study and Cockcroft-Gault equations for sitagliptin dosing.
    McFarland MS; Markley BM; Zhang P; Hudson JQ
    J Nephrol; 2012; 25(4):515-22. PubMed ID: 21928236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database.
    Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
    Curr Med Res Opin; 2010 Jul; 26(7):1697-703. PubMed ID: 20465367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.
    Leiter LA; Carr MC; Stewart M; Jones-Leone A; Scott R; Yang F; Handelsman Y
    Diabetes Care; 2014 Oct; 37(10):2723-30. PubMed ID: 25048383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database.
    Zhang Q; Rajagopalan S; Mavros P; Engel SS; Davies MJ; Yin D; Radican L
    Adv Ther; 2010 Apr; 27(4):223-32. PubMed ID: 20464538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of sotalol prescribing in a community hospital: opportunities for clinical pharmacist involvement.
    Finks SW; Rogers KC; Manguso AH
    Int J Pharm Pract; 2011 Aug; 19(4):281-6. PubMed ID: 21733016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment.
    Eligar VS; Bain SC
    Drug Des Devel Ther; 2013; 7():893-903. PubMed ID: 24039399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of eptifibatide dosing in renal impairment before and after in-service education provided by pharmacists.
    Donovan JL; Schroeder WS; Tran MT; Foster K; Forrest A; Lee TB; Gandhi PJ
    J Manag Care Pharm; 2007 Sep; 13(7):598-606. PubMed ID: 17874866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent trends in the characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large U.S. claims database.
    Brodovicz KG; Kou TD; Alexander CM; O'Neill EA; Senderak M; Engel SS; Girman CJ
    Int J Clin Pract; 2013 May; 67(5):449-54. PubMed ID: 23574104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.
    Herman GA; Mistry GC; Yi B; Bergman AJ; Wang AQ; Zeng W; Chen L; Snyder K; Ruckle JL; Larson PJ; Davies MJ; Langdon RB; Gottesdiener KM; Wagner JA
    Br J Clin Pharmacol; 2011 Mar; 71(3):429-36. PubMed ID: 21284702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.
    Hanefeld M; Herman GA; Wu M; Mickel C; Sanchez M; Stein PP;
    Curr Med Res Opin; 2007 Jun; 23(6):1329-39. PubMed ID: 17559733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes.
    Williams-Herman D; Xu L; Teng R; Golm GT; Johnson J; Davies MJ; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2012 Jan; 14(1):67-76. PubMed ID: 22050786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes.
    Williams-Herman D; Johnson J; Teng R; Golm G; Kaufman KD; Goldstein BJ; Amatruda JM
    Diabetes Obes Metab; 2010 May; 12(5):442-51. PubMed ID: 20415693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
    Wainstein J; Katz L; Engel SS; Xu L; Golm GT; Hussain S; O'Neill EA; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2012 May; 14(5):409-18. PubMed ID: 22059736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study.
    Hong ES; Khang AR; Yoon JW; Kang SM; Choi SH; Park KS; Jang HC; Shin H; Walford GA; Lim S
    Diabetes Obes Metab; 2012 Sep; 14(9):795-802. PubMed ID: 22443183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impacts of a pharmacist-managed outpatient clinic and chemotherapy-directed electronic order sets for monitoring oral chemotherapy.
    Battis B; Clifford L; Huq M; Pejoro E; Mambourg S
    J Oncol Pharm Pract; 2017 Dec; 23(8):582-590. PubMed ID: 27733666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.
    Reasner C; Olansky L; Seck TL; Williams-Herman DE; Chen M; Terranella L; Johnson-Levonas AO; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2011 Jul; 13(7):644-52. PubMed ID: 21410627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
    Williams-Herman D; Johnson J; Teng R; Luo E; Davies MJ; Kaufman KD; Goldstein BJ; Amatruda JM
    Curr Med Res Opin; 2009 Mar; 25(3):569-83. PubMed ID: 19232032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.
    Arechavaleta R; Seck T; Chen Y; Krobot KJ; O'Neill EA; Duran L; Kaufman KD; Williams-Herman D; Goldstein BJ
    Diabetes Obes Metab; 2011 Feb; 13(2):160-8. PubMed ID: 21199268
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.